Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers

BEA-28Positive

AI Analysis

Summary

Beactica Therapeutics AB announced the selection of BEA-28 as a preclinical candidate for its TEAD programme, a first-in-class TEAD degrader targeting biomarker-selected cancers.

Outcome Details

Preclinical candidate selection for TEAD programme

Importance:2/10

Sentiment:

0.60

preclinicalTEAD degraderfirst-in-classprecision medicinecancer

Related Companies

$SHWZ $SOBI.ST $TRAX

Read the original article

Published by PR Newswire Clinical Trials on October 6, 2026 6:21 AM

Read Original